27467556|t|Prevalence and Hospital Management of Amphotericin B Deoxycholate -Related Toxicities during Treatment of HIV - Associated Cryptococcal Meningitis in South Africa
27467556|a|We aimed to establish the prevalence of amphotericin B deoxycholate (AmBd)-related toxicities among South African patients with cryptococcosis and determine adherence to international recommendations to prevent, monitor and manage AmBd -related toxicities. Clinical data were collected from cases of laboratory-confirmed cryptococcosis at 25 hospitals, October 2012 -February 2013. Anemia was defined as hemoglobin (Hb) concentration <10 g/dl, hypokalemia as serum potassium (K) <3.4 mEq/L and nephrotoxicity as an increase in serum creatinine (Cr) to >1.1 times the upper limit of normal. To determine adherence to toxicity prevention recommendations, we documented whether baseline Hb, K and Cr tests were performed, whether pre-emptive hydration and IV potassium chloride (KCl) was administered prior to 80% and 60% of AmBd doses and whether daily oral KCl supplementation was given â‰¥60% of the time. To determine adherence to monitoring recommendations, we ascertained whether a daily fluid chart was completed, Hb was monitored weekly and K or Cr were monitored bi-weekly. Of 846 patients, clinical data were available for 76% (642/846), 82% (524/642) of whom received AmBd. Sixty-four per cent (n = 333) had documented baseline laboratory tests, 40% (n = 211) were given pre-emptive hydration and 14% (n = 72) and 19% (n = 101) received intravenous and oral KCl. While on AmBd, 88% (n = 452) had fluid monitoring; 27% (n = 142), 45% (n = 235) and 44% (n = 232) had Hb, K and Cr levels monitored. Toxicities developed frequently during treatment: anemia, 16% (86/524); hypokalemia, 43% (226/524) and nephrotoxicity, 32% (169/524). AmBd -related toxicities occurred frequently but were potentially preventable with adequate monitoring, supplemental fluid and electrolyte therapies.
27467556	0	10	Prevalence	T081	C0220900
27467556	15	34	Hospital Management	T058	C0019948
27467556	38	65	Amphotericin B Deoxycholate	T109,T121	C0051761
27467556	75	85	Toxicities	T037	C0013221
27467556	93	102	Treatment	T061	C0087111
27467556	106	109	HIV	T047	C0019693
27467556	112	122	Associated	T046	C0243083
27467556	123	146	Cryptococcal Meningitis	T047	C0085436
27467556	150	162	South Africa	T083	C0037712
27467556	189	199	prevalence	T081	C0220900
27467556	203	230	amphotericin B deoxycholate	T109,T121	C0051761
27467556	232	236	AmBd	T109,T121	C0051761
27467556	246	256	toxicities	T037	C0013221
27467556	263	276	South African	T098	C0238605
27467556	277	285	patients	T101	C0030705
27467556	291	305	cryptococcosis	T047	C0010414
27467556	320	329	adherence	T169	C1510802
27467556	333	362	international recommendations	T170	C0681471
27467556	366	373	prevent	T061	C0679698
27467556	375	382	monitor	T058	C0150369
27467556	394	398	AmBd	T109,T121	C0051761
27467556	408	418	toxicities	T037	C0013221
27467556	420	433	Clinical data	T170	C1516606
27467556	439	448	collected	T169	C1516698
27467556	454	459	cases	T081	C0021149
27467556	463	498	laboratory-confirmed cryptococcosis	T047	C0010414
27467556	505	514	hospitals	T073,T093	C0019994
27467556	545	551	Anemia	T047	C0002871
27467556	567	577	hemoglobin	T116,T123	C0019046
27467556	579	581	Hb	T116,T123	C0019046
27467556	583	596	concentration	T081	C1446561
27467556	607	618	hypokalemia	T033	C0020621
27467556	622	637	serum potassium	T059	C0302353
27467556	639	640	K	T059	C0302353
27467556	657	671	nephrotoxicity	T037	C0599918
27467556	678	686	increase	T169	C0442805
27467556	690	706	serum creatinine	T059	C0201976
27467556	708	710	Cr	T059	C0201976
27467556	730	751	upper limit of normal	T081	C1519815
27467556	766	775	adherence	T033	C2364172
27467556	779	787	toxicity	T037	C0013221
27467556	788	798	prevention	T080	C2700409
27467556	799	814	recommendations	T170	C0681471
27467556	838	846	baseline	T081	C1442488
27467556	847	849	Hb	T059	C0518015
27467556	851	852	K	T059	C0236573
27467556	857	865	Cr tests	T059	C0201976
27467556	890	911	pre-emptive hydration	T033	C1321013
27467556	919	937	potassium chloride	T121,T197	C0032825
27467556	939	942	KCl	T121,T197	C0032825
27467556	948	960	administered	T169	C1521801
27467556	961	966	prior	T079	C0332152
27467556	985	989	AmBd	T109,T121	C0051761
27467556	990	995	doses	T081	C0678766
27467556	1008	1013	daily	T079	C0332173
27467556	1014	1022	oral KCl	T200	C3214855
27467556	1023	1038	supplementation	T121	C0561938
27467556	1080	1089	adherence	T169	C1510802
27467556	1093	1119	monitoring recommendations	T061	C3494704
27467556	1146	1151	daily	T079	C0332173
27467556	1152	1163	fluid chart	T061	C0016286
27467556	1179	1181	Hb	T116,T123	C0019046
27467556	1186	1195	monitored	T058	C1283169
27467556	1196	1202	weekly	T079	C0332174
27467556	1207	1208	K	T059	C0302353
27467556	1212	1214	Cr	T059	C0201976
27467556	1220	1229	monitored	T058	C1283169
27467556	1230	1239	bi-weekly	T079	C0585332
27467556	1248	1256	patients	T101	C0030705
27467556	1258	1271	clinical data	T170	C1516606
27467556	1337	1341	AmBd	T109,T121	C0051761
27467556	1388	1396	baseline	T081	C1442488
27467556	1397	1413	laboratory tests	T059	C0022885
27467556	1440	1461	pre-emptive hydration	T033	C1321013
27467556	1506	1517	intravenous	T082	C0013125
27467556	1522	1530	oral KCl	T200	C3214855
27467556	1541	1545	AmBd	T109,T121	C0051761
27467556	1565	1581	fluid monitoring	T061	C0150237
27467556	1634	1636	Hb	T034	C0019029
27467556	1638	1639	K	T034	C0543465
27467556	1644	1653	Cr levels	T033	C0600061
27467556	1654	1663	monitored	T058	C1283169
27467556	1665	1675	Toxicities	T037	C0013221
27467556	1686	1696	frequently	T079	C0332183
27467556	1704	1713	treatment	T061	C0087111
27467556	1715	1721	anemia	T047	C0002871
27467556	1737	1748	hypokalemia	T033	C0020621
27467556	1768	1782	nephrotoxicity	T037	C0599918
27467556	1799	1803	AmBd	T109,T121	C0051761
27467556	1813	1823	toxicities	T037	C0013221
27467556	1824	1832	occurred	T052	C1709305
27467556	1833	1843	frequently	T079	C0332183
27467556	1882	1890	adequate	T080	C0205411
27467556	1891	1901	monitoring	T058	C1283169
27467556	1903	1921	supplemental fluid	T167	C1704353
27467556	1926	1947	electrolyte therapies	T061	C3650834